- Research article
- Open Access
- Open Peer Review
Identification of Achaete-scute complex-like 1 (ASCL1) target genes and evaluation of DKK1 and TPH1 expression in pancreatic endocrine tumours
© Johansson et al; licensee BioMed Central Ltd. 2009
- Received: 1 March 2009
- Accepted: 10 September 2009
- Published: 10 September 2009
ASCL1 role in pancreatic endocrine tumourigenesis has not been established. Recently it was suggested that ASCL1 negatively controls expression of the Wnt signalling antagonist DKK1. Notch signalling regulates expression of TPH1, the rate limiting enzyme in the biosyntesis of serotonin. Understanding the development and proliferation of pancreatic endocrine tumours (PETs) is essential for the development of new therapies.
ASCL1 target genes in the pancreatic endocrine tumour cell line BON1 were identified by RNA interference and microarray expression analysis. Protein expressions of selected target genes in PETs were evaluated by immunohistochemistry.
158 annotated ASCL1 target genes were identified in BON1 cells, among them DKK1 and TPH1 that were negatively regulated by ASCL1. An inverse relation of ASCL1 to DKK1 protein expression was observed for 15 out of 22 tumours (68%). Nine tumours displayed low ASCL1/high DKK1 and six tumours high ASCL1/low DKK1 expression. Remaining PETs showed high ASCL1/high DKK1 (n = 4) or low ASCL1/low DKK1 (n = 3) expression. Nine of twelve analysed PETs (75%) showed TPH1 expression with no relation to ASCL1.
A number of genes with potential importance for PET tumourigenesis have been identified. ASCL1 negatively regulated the Wnt signalling antagonist DKK1, and TPH1 expression in BON1 cells. In concordance with these findings DKK1 showed an inverse relation to ASCL1 expression in a subset of PETs, which may affect growth control by the Wnt signalling pathway.
- Gene Ontology
- Notch Signalling
- BON1 Cell
- Pancreatic Endocrine Tumour
- Microarray Expression Analysis
Pancreatic endocrine tumours (PETs) are derived from the embryologic endoderm and accounts for 1-2% of pancreatic cancer. The only currently curative therapy for patients with PETs is surgical resection. PETs occur sporadically or are familial in nature, caused by germ line mutations in the Multiple endocrine neoplasia 1 (MEN1) or von Hippel-Lindau (VHL) tumour suppressor genes. Understanding the molecular pathways that control PET development and proliferation are essential for possible development of novel therapies.
The basic helix loop helix (bHLH) transcription factor Achaete-scute complex homolog 1 (Ascl1) has been shown to play important regulatory roles in adrenal medullary chromaffin cells , thyroid parafollicular C-cells  and pulmonary endocrine cells . Ascl1 is tightly controlled by the Notch signalling pathway in the developing pancreas and governs the exocrine versus endocrine cell fate decision . Forced Notch activation expands the pool of undifferentiated precursor cells and inhibits the initial emergence of endocrine cells and the following exocrine differentiation [5, 6], whereas disruption of Notch signalling results in precocious endocrine differentiation . The active form of Notch, NICD, induces the expression of Hairy and enhancer of split 1 (HES1) which in turn antagonises the expression of bHLH genes such as ASCL1, with subsequent inhibition of progenitor cell differentiation .
We have recently reported that ASCL1 is invariably expressed in PETs, and suggested that the observed lack of nuclear HES1 might contribute to the expression of ASCL1 in these tumours . In lung cancer cells ASCL1 negatively regulates the expression of Dickkopf homologue 1 (DKK1) , an antagonist of the Wnt/β-catenin signalling pathway which is involved in the development of the exocrine pancreas  and in pancreatic beta cell proliferation . Furthermore, overexpression of NOTCH1 in the human pancreatic endocrine tumour cell line BON1 leads to inhibition of ASCL1 expression, induction of HES1, reduced levels of endocrine markers such as synaptophysin, and also to major repression of TPH1 , the rate limiting enzyme in serotonin biosynthesis. Serotonin is together with other hormones implicated to cause the carcinoid syndrome.
Here we report on ASCL1 target genes in BON1 cells transfected with ASCL1 siRNA. In addition, the relation of DKK1 and TPH1 protein expression to ASCL1 expression is studied in sporadic and familial (MEN 1) PETs.
The polyclonal BON1 cell line (a kind gift from Dr. J. C. Thompson, Department of Surgery, University of Texas Medical Branch, USA) was grown in 1:1 mixture of F12K (Invitrogen, Life Technologies, Carlsbad, USA) and DMEM (SVA, Uppsala, Sweden) medium supplemented with 5% foetal bovine serum. The cells were grown at 37°C in a humidified 5.0% CO2/air atmosphere. siRNA transfections were performed at 80% confluence. The BON1 cell line is one of few human pancreatic endocrine tumour cell lines available .
BON1 cells were seeded on glass cover slips and fixed in 3.7% formaldehyde in phosphate-buffered saline (PBS) (Sigma Aldrich, St Louis, USA) for 30 min, and washed with PBS. The cells were permeabilised in 0.2% Triton X-100 (Sigma) in PBS for 5 min, washed again in PBS, and incubated in 5% foetal bovine serum in PBS for 60 min at room temperature. Primary as well as secondary antibodies were diluted in PBS containing 5% FBS. Cells were incubated with anti-ASCL1 mouse antibody (BD Biosciences, San Jose, USA) or anti-HES1 goat antibody (Santa Cruz Biotechnology, Santa Cruz, USA) followed by FITC-labelled secondary antibodies and TRITC-labelled phalloidin with a washing step in between. The cover slips were mounted on object slides by the use of Vectashield with DAPI (Vector laboratories, Burlingame, USA). Cells were photographed by an Axiocam HRm camera employing the Axiovision imaging software using a 63× plan-apochromat objective and a Zeiss Axioplan2 microscope (Carl Zeiss Inc., Oberkochen, Germany).
The two siRNAs were pre-designed (Ambion, USA, ID 114405 and AM4635). 5'-CGCGUUAUAGUAACUCCCATT and 5'-UGGGAGUUACUAUAACGCGTG (siRNA/A) and 5'-AGUACUGCUUACGAUACGGTT and 5'-TTUCAUGACGAAUGCUAUGCC (Control siRNA). Transfections were performed with 10-30 nmol siRNA in 12 well plates (80 0000 cells/well) using the jetSI-ENDO transfection reagent (Poly-Plus-Transfection SAS, Illkirch, France) according to the manufacturer's protocol. Samples were not pooled for downstream applications.
RNA isolation and cDNA synthesis
Cells were harvested 72 hours after transfection and total RNA was extracted using TriZol Reagent (Invitrogen) according to manufacturer's instructions. The RNA concentration and quality were assessed using the Agilent Bioanalyser (Agilent Technologies, Palo Alto, USA). The RNeasy Mini Kit (Qiagen, Holden, Germany) was used to further purify the RNA samples. cDNA was synthesised from 1 μg of total RNA using the High Capacity cDNA Archive Kit (Applied Biosystems, Foster City, USA) according to the manufacturer's instructions.
Quantitative real-time PCR (qPCR)
Relative mRNA expression was determined by qPCR, and compared to positive controls comprising lung carcinoid cell lines H727 and H720 (CRL-5815 and CRL-5838, LGC Promochem, Middlesex, UK. Data not shown). Commercially available primer and probe sets were used and measured against standard curves generated from dilution series of cDNA from cell lines H727, H720 and BON1. The following primers/probe mixes were used: ASCL1; Hs00269932_m1, TCF3; Hs01016249_m1, DLL1; Hs 00194509_m1, SYP; Hs00300531_m1, TPH1; Hs00188220_m1, and DKK1; Hs00183740_m1 (Applied Biosystems). Reactions were performed and analysed using an Applied Biosystems PRISM 7700 Sequence Detector. Standard cycling conditions were used. Triplicate of each cDNA was used and each assay was performed twice. The gene-specific signals were normalised to expression of ACTB and PPIA endogenous control genes (primer/probe mix 4333762F and 4333763T).
Protein extracts for Western blotting were prepared by lysing the cells in RIPA buffer (Sigma-Aldrich) supplemented with complete protease inhibitor cocktail (Roche Diagnostics, Basel, Switzerland). Protein sample from each transfected well was separated in 12% SDS-polyacrylamide gradient gels (BioRad, Hercules, USA), transferred to PVDF membranes (GE Healthcare Europe GmbH, Uppsala, Sweden) and blocked with SuperBlock Blocking Buffer (Pierce Biotechnology, Rockford, USA) overnight at 4°C. The membranes were incubated with anti-ASCL1 monoclonal antibody (BD Biosciences) or anti-α- Tubulin monoclonal antibody (Santa Cruz Biotechnology) for 2 h. After briefly washing with PBS containing 0.1% Tween 20, the filters were incubated for 1 h with a secondary goat anti mouse antibody conjugated to horseradish peroxidase (1:5000 dilution). The filters were washed and developed using the Super Signal West femto kit (Pierce Biotechnology).
RNAs from successful siRNA transfection experiments where used for microarray expression analysis. The GeneChips, Human Genome U133 Plus 2.0 (Affymetrix, Santa Clara, USA) was used for the analysis. 100 nanograms of total RNA from each sample were used to prepare biotinylated fragmented cRNA using the two-cycle cDNA synthesis part. GeneChip were hybridised for 16 hours in a 45°C incubator, rotated at 60 rpm according to the GeneChip Expression Analysis Technical Manual (Rev. 5, Affymetrix). The arrays were washed and stained using the Fluidics Station 450 and finally scanned using the GeneChip Scanner 3000 7 G.
Differentially regulated genes were determined by calculating the fold change between the nonspecific siRNA transfected cell samples and the siRNA-ASCL1 transfected samples. Subsequent analysis of the gene expression data was carried out in the freely available statistical computing language R http://www.r-project.org using packages available from the Bioconductor project http://www.bioconductor.org. The raw data was normalised using the robust multi-array average (RMA)  background-adjusted, normalized and log-transformed summarised values as first suggested by Li and Wong in 2001 . In order to search for the differentially expressed genes between the samples from the different groups an empirical Bayes moderated t test was then applied , using the 'limma' package . To address the problem with multiple testing, the p-values were adjusted according to Benjamini and Hochberg . We selected as significant only probe sets with an adjusted p-value < 0.01 and an abs (log2ratio) equal to or larger than1 (which corresponds to a two-fold change in expression) to investigate further.
Pancreatic endocrine tumour specimens were obtained from biobanks at the Department of Endocrine Oncology, the Department of Surgery, and the Department of Pathology at the Uppsala University Hospital. Frozen or paraffin embedded tissues were used. Tumours were initially frozen in liquid nitrogen and stored at -80°C until analysis. Inclusions were based on the availability of operative tissue specimens or biopsy material. Altogether two gastrinomas, two glucagonomas (one liver metastasis), five insulinomas and 14 non-functioning tumours were investigated. The mean age at diagnosis was 48 years (range 19-86). Seven tumours were from MEN 1 patients. The tumours were classified according to the WHO classification of endocrine neoplasms. For comparison, eight specimens of macroscopically determined non-tumourous pancreas adjacent to a pancreatic endocrine tumour were assessed by immunohistochemistry.
Twenty-two PETs were immunostained for DKK1. Frozen, acetone-fixed sections (6 μm) were incubated with an anti-DKK1 rabbit polyclonal antibody (SC-25516, Santa Cruz Biotechnology) diluted in PBS with 1% BSA. The reaction product was revealed using a biotinylated secondary antibody, Vectastain Elite ABC, (Vector) and the chromogen 3-amino-9-ethylcarbazol and 0.02% hydrogen peroxide as a substrate. Sections were counterstained with Mayer's haematoxylin and mounted. Twelve paraffin embedded PET specimens were immunostained for TPH1. The rehydrated sections were heat-retrieved and incubated with an anti-TPH1 mouse antibody (Sigma Aldrich). The reaction product was revealed using the EnVision system -HPR (DakoCytomation, Copenhagen, Denmark), and DAB as the chromogen. Sections were counterstained with Mayer's haematoxylin and mounted. Each PET specimen and non-tumourous pancreatic specimens were evaluated independently by the authors and graded as low, high or heterogeneous (i.e. areas of both low and high expression present in the tumour). Immunostaining for ASCL1 has been published previously  and was graded as negative (-), weak (+), moderate (++), or strong (+++). In the present study we denoted strong (+++) staining in the cytoplasm as High and weak or moderate (+/++) as Low. Sections were photographed by an AxioCam MR camera employing the Axiovision imaging software using a LD A-plan 20×/40× 0.30 Ph1 objectives and a Zeiss Axiovert 40 microscope (Carl Zeiss Inc.).
Unpaired t test was used for calculations regarding qPCR expression. A p-value below 0.05 was considered significant.
Permission for this study was obtained from the Uppsala Ethical Committee, Sweden. Informed consent was gathered from all patients.
Expression profiling in the pancreatic endocrine tumour cell line BON1
Annotated genes with increased expression in BON1 cells transfected with siRNA to ASCL1
adj p Value
RNA binding motif protein 24
hyaluronan synthase 2
v-myc myelocytomatosis viral related oncogene,
chromosome 13 open reading frame 15
adenomatosis polyposis coli down-regulated 1
leucine-rich repeat-containing G protein-coupled receptor 5
dickkopf homolog 1 (Xenopus laevis)
Tryptophan hydroxylase 1
Inhibitor of DNA binding 4
poliovirus receptor-related 3
TIMP metallopeptidase inhibitor 2
adipocyte-specific adhesion molecule
sparc/osteonectin, cwcv and kazal-like domains
glycerol-3-phosphate dehydrogenase 2 (mitochondrial)
chloride intracellular channel 5
EMG1 nucleolar protein homolog (S. cerevisiae)
dopamine receptor D1 interacting protein
chemokine (C-X-C motif) receptor 7
stomatin (EPB72)-like 3
fibroblast growth factor 13
choroideremia (Rab escort protein 1)
glucuronic acid epimerase
glycerol-3-phosphate dehydrogenase 2 (mitochondrial)
hypothetical protein LOC283454
chromosome X open reading frame 57
prostaglandin E synthase 3 (cytosolic)
heparan sulfate 2-O-sulfotransferase 1
epithelial membrane protein 1
estrogen receptor binding site associated, antigen, 9
vacuolar protein sorting 37 homolog B (S. cerevisiae)
nephroblastoma overexpressed gene
Annotated genes with decreased expression in BON1 cells transfected with siRNA to ASCL1
adj P Value
family with sequence similarity 87, member A
Hypothetical protein DKFZp761C1711
gamma-aminobutyric acid (GABA) A receptor, alpha 1
glucuronidase, beta pseudogene 1
trophoblast-derived noncoding RNA
Similar to Beta-glucuronidase precursor
tubulin tyrosine ligase-like family, member 5
Early B-cell factor 1
Vacuolar protein sorting 13 homolog C (S. cerevisiae)
Ring finger protein 12
achaete-scute complex homolog 1 (Drosophila)
sorbin and SH3 domain containing 2
v-erb-a erythroblastic leukemia viral oncogene homolog 4
hypothetical protein FLJ38379
Transcription factor 12
Ras-like without CAAX 1
Zinc finger, CCHC domain containing 7
hypothetical protein LOC730168///LOC732289
CASP8 and FADD-like apoptosis regulator
chromosome 11 open reading frame 80
Cell division cycle and apoptosis regulator 1
family with sequence similarity 81, member B
hypothetical protein FLJ25770
SMA4///similar to SMA4
Zinc finger, AN1-type domain 6
hypothetical protein LOC728555///LOC730391
GRAM domain containing 3
core-binding factor, runt domain, alpha subunit 2
Zinc finger protein 638
hypothetical protein LOC728678///LOC731914
chloride channel 5
hypothetical protein FLJ23556
Phosphonoformate immuno-associated protein 5
protocadherin gamma subfamily A, 4
hypothetical protein LOC145474
hypothetical gene LOC283846
thioredoxin interacting protein
CDC14 cell division cycle 14 homolog B
RUN and FYVE domain containing 2
Kelch-like 28 (Drosophila)
Muscleblind-like 2 (Drosophila)
hypothetical protein LOC730496
protein kinase, AMP-activated, alpha 1 catalytic subunit
nuclear receptor subfamily 5, group A, member 2
similar to calpain 8
Protein tyrosine phosphatase, non-receptor type 13
RAS protein activator like 2
neuroblastoma breakpoint family, member 1, 3, 8, 10
Zinc finger protein 518
sodium channel, nonvoltage-gated 1 alpha
CTAGE family, member 5
similar to LIM and senescent cell antigen-like domains 3
Pellino homolog 1 (Drosophila)
Family with sequence similarity 98, member A
bromodomain and WD repeat domain containing 2
chromosome 20 open reading frame 74
metastasis associated lung adenocarcinoma transcript 1
Similar to lymphocyte-specific protein 1
chromosome Y open reading frame 15B
SPARC related modular calcium binding 2
calpain 2, (m/II) large subunit
DNA helicase HEL308
Programmed cell death 6
hypothetical protein LOC285147
trefoil factor 3 (intestinal)
RIMS binding protein 2
chromosome 10 open reading frame 93
succinate receptor 1
hypothetical protein LOC151878
Leucine rich repeat (in FLII) interacting protein 1
ADAM metallopeptidase domain 12 (meltrin alpha)
plasminogen-like B2///plasminogen-like B1
polymerase (DNA directed), theta
ADAM metallopeptidase domain 28
Musashi homolog 2 (Drosophila)
jumonji domain containing 1C
5'-nucleotidase, ecto (CD73)
lysosomal trafficking regulator
Spleen tyrosine kinase
Discs, large homolog 1 (Drosophila)
Ras association (RalGDS/AF-6) domain family 6
ubiquitin-conjugating enzyme E2D 3
transmembrane protein 46
tetratricopeptide repeat domain 30A
Synaptosomal-associated protein, 25 kDa
hypothetical protein PRO2852
myeloid/lymphoid or mixed-lineage leukemia
RNA binding motif protein 6
protein phosphatase 2, regulatory subunit B',
Golgi associated PDZ and coiled-coil motif containing
laminin, alpha 4
splicing factor, arginine/serine-rich 15
kinesin family member 13A
cytoplasmic linker associated protein 2
Methylmalonic aciduria (cobalamin deficiency) cblA type
chromosome 1 open reading frame 192
SPARC related modular calcium binding 1
REV3-like, catalytic subunit of DNA polymerase zeta
SMAD family member 1
twinfilin, actin-binding protein, homolog 1 (Drosophila)
F-box protein 9
Functional GO categories
No. of genes or transcripts
Regulation of biological or cellular process
Cellular metabolic process
Transcription and regulation of transcription
Regulation of nucleo -base -side, -tide and nucleic acid metabolic process
Regulation of gene expression
Locomotion, cellular or regulation of
Protein amino acid phosphorylation
Carbohydrate biosynthetic process
Integrin-mediated signalling pathway
Binding activity, receptor, DNA, nucleic acid
Transcription regulation/cofactor or binding activity
Ligase activity ubiquitin/amino acid/small conjugating protein
Enzyme activator activity
Transmembrane receptor protein kinase activity
Inverse expression of ASCL1 and DKK1 in the majority of investigated PETs
Clinical characteristics and results of immunohistochemistry for ASCL1, DKK1 and TPH1
TPH1 displays heterogeneous expression with no relation to ASCL1 in PETs
The amount of immunoreactivity varied for TPH1. Nine out of the twelve analysed PETs (75%) showed a heterogeneous expression pattern (Figure 6F, Table 4). High expression was seen in two tumours and low expression in one. Tumours with high or heterogeneous expression showed a somewhat lower TPH1 expression than control non-tumourous pancreatic tissue. No relations of ASCL1 to TPH1 expression or to clinical characteristics were observed.
This study showed altogether 433 target transcripts (158 annotated genes) in the human pancreatic endocrine tumour cell line BON1 that directly or indirectly were regulated by ASCL1, among them several putative oncogenes and suppressor genes. ASCL1 was found to negatively regulate DKK1 and TPH1 expression in BON1 cells. This may suggest that Notch1 signalling pathway regulatory factor(s) other than ASCL1 is involved in the reduced expression of TPH1 observed in Notch1 overexpressing BON cells . In order to investigate if this relation between ASCL1, DKK1 and TPH1 in vitro might be of relevance in vivo, we analysed their protein expression in PETs. An inverse relation of ASCL1 to DKK1 expression was observed in 68% of the analysed tumours (n = 22). No obvious relation between ASCL1 and TPH1 expression levels was found.
ASCL1 has been found to repress DKK1 transcription, a negative regulator of the Wnt signalling pathway in lung cancer cells, and is also the first transcriptional repressor identified for DKK1. The regulation is meditated by histone deacetylation and repressive lysine 27 trimetylation in the promoter region of DKK1 . Moreover, downregulation of DKK1 has been associated with colorectal- and breast cancer (23, 24). On the other hand, DKK1 has also been identified as a potential prognostic and diagnostic marker for cohorts of breast cancer patients with poor prognosis  and increased circulating levels of DKK1 has been associated with the presence of bone metastases in patients with breast cancer  We note that 13 out of the 22 analysed PETs prominently expressed DKK1.
Wnt/β-catenin signalling is negatively regulated by DKK1 by inhibition of the complex formation between Wnts and its receptors, LRP5/6. It has been advocated that ASCL1 expression may favour cancer cell growth through repression of DKK1 with the consequential aberrant activation of the Wnt/β-catenin signalling pathway . This may also apply to a subset of PETs as a total of 9 out of 22 PETs displayed low DKK1 immunoreactivity.
ASCL1 may have a coordinating role in production of serotonin by transcriptional regulation of TPH1 and could thereby be involved in causing the carcinoid syndrome in patients with PET . Our results from the microarray expression analysis in BON1 cells suggested that TPH1 might constitute a ASCL1 target gene in BON1 cells. However, an obvious relation between ASCL1 and TPH1 protein expression levels were not found, and TPH1 showed a heterogeneous pattern of immunoreactivity in PETs.
Traditionally, much of the Notch signalling research has focused on the involvement of Notch signalling factors like ASCL1 in neural stem cell differentiation. Even though pancreatic endocrine cells have an endodermal origin they also share several molecular features with neurons. Like neurons in the central nervous system, differentiating endocrine cells in the pancreas appear in a scattered fashion within a field of progenitor cells. The different cell types are generated by lateral inhibition through Notch signalling . With this in mind it is not surprising that the results from the GO analysis suggest that ASCL1 target genes participate in cellular differentiation, migration and localisation of cells also in pancreatic endocrine cells.
The present findings support the notion that ASCL1 is involved in pancreatic endocrine tumourigenesis, where aberrant expression of DKK1 may play additional important roles. ASCL1 also directly or indirectly regulates expression of several putative oncogenes and tumours suppressor genes in pancreatic endocrine tumour cells that may contribute to the neoplastic process.
This work was supported by the Swedish Research Council, Swedish Cancer Society, and Lions Fund for Cancer Research. The authors are grateful to B. Bondeson, Dr. C. Martijn (Department of Surgical Sciences), A. von Malmborg, Dr J. Saras (Department of Medical Sciences) and H. Göransson (Uppsala Array Platform) for excellent experimental support and technical expertise. The BON1 cell line was kindly provided by Dr. J. C. Thompson (Department of Surgery, University of Texas Medical Branch, USA).
- Huber K, Bruhl B, Guillemot F, Olson EN, Ernsberger U, Unsicker K: Development of chromaffin cells depends on MASH1 function. Development. 2002, 129: 4729-4738.PubMedGoogle Scholar
- Lanigan TM, DeRaad SK, Russo AF: Requirement of the MASH-1 transcription factor for neuroendocrine differentiation of thyroid C cells. J Neurobiol. 1998, 34: 126-134. 10.1002/(SICI)1097-4695(19980205)34:2<126::AID-NEU3>3.0.CO;2-4.View ArticlePubMedGoogle Scholar
- Borges M, Linnoila RI, Velde van de HJ, Chen H, Nelkin BD, Mabry M, Baylin SB, Ball DW: An achaete-scute homologue essential for neuroendocrine differentiation in the lung. Nature. 1997, 386: 852-855. 10.1038/386852a0.View ArticlePubMedGoogle Scholar
- Apelqvist A, Li H, Sommer L, Beatus P, Anderson DJ, Honjo T, Hrabe de Angelis M, Lendahl U, Edlund H: Notch signalling controls pancreatic cell differentiation. Nature. 1999, 400: 877-881. 10.1038/23716.View ArticlePubMedGoogle Scholar
- Murtaugh LC, Stanger BZ, Kwan KM, Melton DA: Notch signalling controls multiple steps of pancreatic differentiation. Proc Natl Acad Sci USA. 2003, 100: 14920-14925. 10.1073/pnas.2436557100.View ArticlePubMedPubMed CentralGoogle Scholar
- Esni F, Ghosh B, Biankin AV, Lin JW, Albert MA, Yu X, MacDonald RJ, Civin CI, Real FX, Pack MA, Ball DW, Leach SD: Notch inhibits Ptf1 function and acinar cell differentiation in developing mouse and zebrafish pancreas. Development. 2004, 131: 4213-4224. 10.1242/dev.01280.View ArticlePubMedGoogle Scholar
- Iso T, Kedes L, Hamamori Y: HES and HERP families: multiple effectors of the Notch signalling pathway. J Cell Physiol. 2003, 194: 237-255. 10.1002/jcp.10208.View ArticlePubMedGoogle Scholar
- Johansson T, Lejonklou MH, Ekeblad S, Stålberg P, Skogseid B: Lack of Nuclear Expression of Hairy and Enhancer of Split-1 (HES1) in Pancreatic Endocrine Tumours. Horm Metab Res. 2008, 40: 354-359. 10.1055/s-2008-1076695.View ArticlePubMedGoogle Scholar
- Osada H, Tomida S, Yatabe Y, Tatematsu Y, Takeuchi T, Murakami H, Kondo Y, Sekido Y, Takahashi T: Roles of achaete-scute homologue 1 in DKK1 and E-cadherin repression and neuroendocrine differentiation in lung cancer. Cancer Res. 2008, 68: 1647-1655. 10.1158/0008-5472.CAN-07-5039.View ArticlePubMedGoogle Scholar
- Wells JM, Esni F, Boivin GP, Aronow BJ, Stuart W, Combs C, Sklenka A, Leach SD, Lowy AM: Wnt/beta-catenin signalling is required for development of the exocrine pancreas. BMC Dev Biol. 2007, 7: 4-10.1186/1471-213X-7-4.View ArticlePubMedPubMed CentralGoogle Scholar
- Rulifson IC, Karnik SK, Heiser PW, ten Berge D, Chen H, Gu X, Taketo MM, Nusse R, Hebrok M, Kim SK: Wnt signalling regulates pancreatic beta cell proliferation. Proc Natl Acad Sci USA. 2007, 104: 6247-6252. 10.1073/pnas.0701509104.View ArticlePubMedPubMed CentralGoogle Scholar
- Nakakura EK, Sriuranpong VR, Kunnimalaiyaan M, Hsiao EC, Schuebel KE, Borges MW, Jin N, Collins BJ, Nelkin BD, Chen H, Ball DW: Regulation of neuroendocrine differentiation in gastrointestinal carcinoid tumour cells by notch signalling. J Clin Endocrinol Metab. 2005, 90: 4350-4356. 10.1210/jc.2005-0540.View ArticlePubMedGoogle Scholar
- Parekh D, Ishizuka J, Townsend CM, Haber B, Beauchamp RD, Karp G, Kim SW, Rajaraman S, Greeley G, Thompson JC: Characterization of a human pancreatic carcinoid in vitro: morphology, amine and peptide storage, and secretion. Pancreas. 1994, 9: 83-90. 10.1097/00006676-199401000-00013.View ArticlePubMedGoogle Scholar
- Irizarry RA, Hobbs B, Collin F, Beazer-Barclay YD, Antonellis KJ, Scherf U, Speed TP: Exploration, normalization, and summaries of high density oligonucleotide array probe level data. Biostatistics. 2003, 4: 249-264. 10.1093/biostatistics/4.2.249.View ArticlePubMedGoogle Scholar
- Li C, Wong WH: Model-based analysis of oligonucleotide arrays: expression index computation and outlier detection. Proc Natl Acad Sci USA. 2001, 98: 31-36. 10.1073/pnas.011404098.View ArticlePubMedGoogle Scholar
- Smyth GK: Linear models and empirical Bayes methods for assessing differential expression in microarray experiments. Stat Appl Genet Mol Biol. 2004, 3: Article 3-Google Scholar
- Wettenhall JM, Smyth GK: LimmaGUI: a graphical user interface for linear modelling of microarray data. Bioinformatics. 2004, 20: 3705-3706. 10.1093/bioinformatics/bth449.View ArticlePubMedGoogle Scholar
- Hochberg Y, Ba Y: Controlling the false discovery rate: A practical and powerful approach to multiple testing. J Roy Stat Soc Ser B. 1995, 57: 289-300.Google Scholar
- Kunisch M, Haenlin M, Campos-Ortega JA: Lateral inhibition mediated by the Drosophila neurogenic gene delta is enhanced by proneural proteins. Proc Natl Acad Sci USA. 1994, 91: 10139-10143. 10.1073/pnas.91.21.10139.View ArticlePubMedPubMed CentralGoogle Scholar
- Castro DS, Skowronska-Krawczyk D, Armant O, Donaldson IJ, Parras C, Hunt C, Critchley JA, Nguyen L, Gossler A, Göttgens B, Matter JM, Guillemot F: Proneural bHLH and Brn proteins coregulate a neurogenic program through cooperative binding to a conserved DNA motif. Dev Cell. 2006, 11: 831-844. 10.1016/j.devcel.2006.10.006.View ArticlePubMedGoogle Scholar
- Johnson JE, Birren SJ, Saito T, Anderson DJ: DNA binding and transcriptional regulatory activity of mammalian achaete-scute homologous (MASH) proteins revealed by interaction with a muscle-specific enhancer. Proc Natl Acad Sci USA. 1992, 89: 3596-3600. 10.1073/pnas.89.8.3596.View ArticlePubMedPubMed CentralGoogle Scholar
- Persson P, Jogi A, Grynfeld A, Pahlman S, Axelson H: HASH-1 and E2-2 are expressed in human neuroblastoma cells and form a functional complex. Biochem Biophys Res Commun. 2000, 274: 22-31. 10.1006/bbrc.2000.3090.View ArticlePubMedGoogle Scholar
- Forget MA, Turcotte S, Beauseigle D, Godin-Ethier J, Pelletier S, Martin J, Tanguay S, Lapointe R: The Wnt pathway regulator DKK1 is preferentially expressed in hormone-resistant breast tumours and in some common cancer types. Br J Can. 2007, 96: 646-653. 10.1038/sj.bjc.6603579.View ArticleGoogle Scholar
- González-Sancho JM, Aguilera O, García JM, Pendás-Franco N, Peña C, Cal S, García de Herreros A, Bonilla F, Muñoz A: The Wnt antagonist DICKKOPF-1 gene is a downstream target of beta-catenin/TCF and is down regulated in human colon cancer. Oncogene. 2005, 24: 1098-1103. 10.1038/sj.onc.1208303.View ArticlePubMedGoogle Scholar
- Voorzanger-Rousselot N, Goehrig D, Journe F, Doriath V, Body JJ, Clézardin P, Garnero P: Increased Dickkopf-1 expression in breast cancer bone metastases. Br J Cancer. 2007, 97: 964-970.PubMedPubMed CentralGoogle Scholar
- The pre-publication history for this paper can be accessed here:http://0-www.biomedcentral.com.brum.beds.ac.uk/1471-2407/9/321/prepub
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.